Hematology

CAR-T

Questions discussed in this category

How do you choose between liso-cel and axi-cel in patients with early relapse DLBCL for whom you are recommending CAR T-cell therapy?

3 Answers available

What are your top takeaways in Hematologic Malignancies from ASH 2024?

12 Answers available

How do you incorporate CAR-T cell therapy for DLBCL in transplant-eligible patients?

Given the results of ZUMA-7, TRANSFORM, and BELINDA - how does this inform your current practice? What are the currently approved indications for CAR-...

6 Answers available

How would you manage relapsed DLBCL in a patient who received second line CD19 CART treatment?

3 Answers available

What are your practical considerations for incorporating bispecific antibody therapy into treatment of relapsed DLBCL?

4 Answers available

What is your approach to AYA patients with B-cell ALL who relapse after CD19 CAR-T?

2 Answers available

What criteria is needed in relapsed/refractory B-cell ALL to choose CAR-T therapy over conventional stem cell transplant as destination therapy?

3 Answers available

How do different inflammatory markers like CRP and ferritin contribute differently, if at all, to the monitoring of CART neurotoxicity?

1 Answer available

What antibiotic, antifungal and antiviral prophylaxis you give post CAR-T therapy, and what is the duration?

1 Answer available

Would you offer XRT as bridging for all patients with limited pre CAR-T disease or as consolidation for only those with residual PET-avidity on day+30 post CAR-T?

1 Answer available

Is there an optimal salvage radiation dose for relapsed post-CART disease?

1 Answer available

Would you offer bridging radiation before or after leukapheresis?

Are you concerned about cases where radiation has to be started urgently before leukapheresis?

1 Answer available

How soon after CAR T-cell therapy can salvage radiation be delivered?

3 Answers available

How are you deciding between available third line therapies for post-transplant relapsed DLBCL?

In a patient who relapsed following 2nd line transplant, how do you select CAR-T vs bispecifics vs non-T-cell-mediated therapies as outlined in NCCN? ...

1 Answer available

How should community oncologists practically counsel patients with aggressive lymphomas on the potential treatment course as they move into 2L/3L therapies?

Do you speak to different expectations re: ability to achieve PR/CR and/or how this will impact ability to get to later therapies for a patient with p...

1 Answer available

Is there an optimal bridging radiation dose for aggressive B-cell NHL undergoing CAR T-cell therapy?

What influences your decision to proceed with palliative vs. definitive, and standard vs. hypofractionation dosing regimens?

2 Answers available

Which patients with relapsed/refractory NHL are appropriate for pre-CAR-T bridging radiation therapy?

2 Answers available

How do you approach evaluation and management of arthralgia in a patient after CAR-T cell therapy?

1 Answer available

How do you approach diagnosis and treatment of HLH/MAS following CAR T-cell therapy?

How is this entity distinct from other secondary HLH entities?

2 Answers available

How would you manage a transplant-eligible patient with DLBCL who relapsed 6-12 months following a CR1 to R-CHOP and then attained a CR2 to platinum-based salvage chemoimmunotherapy?

How do you choose between CAR-T and autoSCT, for example?

3 Answers available

How would you treat a fit patient with a history of relapsed CLL who now presents with Richter transformation s/p autologous anti-CD19 chimeric antigen receptor (CAR) T-cells?

1 Answer available

Is there a role for IL2-receptor antagonists and TNF-alpha inhibitors in cytokine release syndrome as a complication of CAR-T or immunotherapy?

1 Answer available

What is the best approach for patients with DLBCL with early relapse (< 6 months) after initially attaining a CR with 6 cycles RCHOP?

Does this differ for a patient who had a longer remission before relapse?

4 Answers available

What is your treatment of choice for triple class refractory multiple myeloma?

CAR-T (any specific preference of product?) vs bispecific antibodies vs any other specific agents not previously utilized?

2 Answers available

Papers discussed in this category

Blood, 2022 Mar 03

Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission.

Frontiers in immunology, 2023 Jan 17

Efficacy of chimeric antigen receptor T cell therapy and autologous stem cell transplant in relapsed or refractory diffuse large B-cell lymphoma: A systematic review.

N Engl J Med, 2021 Dec 11

Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.

Lancet,

Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial.

N Engl J Med, 2022 Dec 11

Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

J Clin Oncol, 2022 Dec 22

Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial.

Blood Adv, 2022 May 10

A multicenter retrospective study of polatuzumab vedotin in patients with large B-cell lymphoma after CAR T-cell therapy.

Blood, 2022 Dec 15

Outcomes of patients with aggressive B-cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T analysis.

J Clin Oncol, 2021 Dec 9

Disease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium Report.

Blood Cancer Discov, 2021 Dec 01

Next-Generation Sequencing of Minimal Residual Disease for Predicting Relapse after Tisagenlecleucel in Children and Young Adults with Acute Lymphoblastic Leukemia.

Leukemia, 2025 May

Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3.

J Clin Oncol, 2025 Feb 10

Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL.

The New England journal of medicine, 2024 Nov 27

Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia.

Exp Hematol Oncol, 2021 Feb 19

Etanercept as a new therapeutic option for cytokine release syndrome following chimeric antigen receptor T cell therapy.

Blood Adv,

Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma.

Radiother Oncol, 2021 Dec 7

Does bridging radiation therapy affect the pattern of failure after CAR T-cell therapy in non-Hodgkin lymphoma?

Int J Radiat Oncol Biol Phys, 2021 Dec 1

Patterns and Predictors of Failure in Recurrent or Refractory Large B-Cell Lymphomas After Chimeric Antigen Receptor T-Cell Therapy.

Int J Radiat Oncol Biol Phys, 2022 Dec 20

Don't put the CART before the horse: The role of radiation therapy in peri-CAR T-cell therapy for aggressive B-cell non-Hodgkin lymphoma.

Transplant Cell Ther, 2022 Dec 30

Bridging Radiation Rapidly and Effectively Cytoreduces High-Risk Relapsed/Refractory Aggressive B Cell Lymphomas Prior to Chimeric Antigen Receptor T Cell Therapy.

Blood advances, 2020 Jul 28

High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2022 Oct 26

Radiation prior to chimeric antigen receptor T-cell therapy is an optimizing bridging strategy in relapsed/refractory aggressive B-cell lymphoma.

Blood advances, 2020 Nov 24

Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma.

J Hematol Oncol, 2022 Mar 26

Metabolic characteristics and prognostic differentiation of aggressive lymphoma using one-month post-CAR-T FDG PET/CT.

Blood advances, 2022 May 10

Day 30 SUVmax predicts progression in patients with lymphoma achieving PR/SD after CAR T-cell therapy.

Cancer, 2023 Jun 24

Determinants of frontline tyrosine kinase inhibitor choice for patients with chronic-phase chronic myeloid leukemia: A study from the Registro Italiano LMC and Campus CML.

The New England journal of medicine, 2024 Jun 03

Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.

Nature medicine, 2024 Jun 03

Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial.

Related Topics in Hematology